Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Hematologic malignancies Clinical Trials

Protocol Number Title
1999LS060
MT1999-14 Unrelated or partially matched allogeneic donor stem cells for lymphoma, myeloma, and chronic lymphocytic leukemia
2003NT036
ALTE03N1 Key Adverse Events After Childhood Cancer (COG study)
2009NTCG026
COG ALTE05N1 Umbrella Long-Term Follow-Up Protocol
2009NTUC056
Childhood Cancer Survivor Study
2010NTLS145
MT2007-05R Late Effects in Survivors of Cancer, Stem Cell Transplantation or Blood Disorders From Digital Upgrade to Digital Revolution: A New Era in Survivor Research
2012CG016
MT2012-01 : A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients with Hematologic Malignancies BMT CTN PROTOCOL 1101
2012NTLS130
MT2013-03R Impact Of Gender And Frailty On Hematopoietic Cell Transplant
2012OC065
MT2012-11C: Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
2013CG111
COG ANHL12P1 - A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117
2013LS081
HM2013-24: Study of the ADAM17 Inhibitor INCB7839 Combined With Rituximab After Autologous Hematopoietic Cell Transplantation (HCT) For Patients With Diffuse Large B Cell Non-Hodgkin Lymphoma (DLBCL)
2013NTUC039
BMT Long-Term Follow-up Study -2
2013OC003
MT2013-06C : Treatment of graft Failure after HSCT
2013OC013
MT2013-09C : Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for the Treatment of Hematological Diseases
2014CG023
COG ADVL1312 - A PHASE 1/2 STUDY OF AZD1775 (MK-1775 , IND# 121422) IN COMBINATION WITH ORAL IRINOTECAN IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY SOLID TUMORS
2014LS020
MT2014-12:Phase I/II Study of Human Chorionic Gonadotropin and Epidermal Growth Factor Supplementation (Pregnyl?) to Support Tolerance and Repair As Adjunct Therapy in High-Risk or Refractory Acute Graft-Versus-Host Disease
2014LS093
HM2014-26 DT2219 immunotoxin for the treatment of relapsed or refractory CD19 (+) and/or CD 22 (+) B-lineage leukemia or lymphoma
2014NTLS071
Family-based studies of susceptibility to early onset disease
2015CG012
COG ADVL1412 - A Phase 1/2 Study of Nivolumab (IND# 124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab Additional Title: ADVL1412-Bristol-Myers Squibb Company
2015CG046
COG AHOD1331 - A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults "AHOD1331 Seattle Genetics"
2015IS075
HM2015-18: A phase 1/2 study of ALT-803 in patients with relapse/refractory indolent B cell non-Hodgkin lymphoma in conjunction with rituximab
2015LS057
MT2015-46 : A Phase I Trial Testing NAM Expanded Haploidentical or Mismatched Related Donor Natural Killer (NK) Cells Followed by a Short Course of IL-2 for the Treatment of Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma
2015LS149
MT2015-17C :Transplantation of Umbilical Cord Blood from Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen
2015LS152
MT2015-32C : Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) for the Treatment of Hematological Diseases
2015NTCG168
COG APEC14B1 The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study Additional Title: EVERYCHILD (APEC14B1) PCR - COG Foundation
2015NTIS003
MT2015-16R:Novartis CCTL019A2205B; MT2015-16R: Long Term Follow-Up of Patients Exposed to Lentiviral- Based CD19 directed CART Cell Therapy
2015NTLS018
MT2015-08R: Microbial, Graft and Host Interactions in Hematopoietic Cell Transplantation Reducing sepsis-related mortality in cancer patients through microbiome therapy
2015NTLS158
An advance care planning intervention for adolescent and young adult patients undergoing bone marrow transplant
2016CG084
COG ALTE1621: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial Additional Title: NIH Grant 1R01CA196854: ALTE1621
2016CG156
COG ADVL1513 - A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
2016IS027
MT2016-33 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Corticosteroids in Patients with New Onset Chronic Graft Versus Host Disease (cGVHD)
2016IS041
HM2016-16 : Multicenter Expanded Access Protocol of Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs) for Patients with EBV-Associated Viremia or Malignancies for Whom There are No Appropriate Alternative Therapies
2016IS069
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects with Advanced Malignancies
2016LS132
MT2016-11C: Autologous Stem Cell Transplant In Patients with Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphomas (NHL)
2016NTLS144
The Development of Data Capture Methodologies in Pediatric Cancer Patients Treated with Targeted Agents and Immunotherapies: Leveraging the Research Infrastructure of a Childhood Cancer Survivor Program
2017CG026
MT2017-10 :A RANDOMIZED DOUBLE-BLIND PHASE III STUDY OF IBRUTINIB DURING AND FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION VERSUS PLACEBO IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA OF THE ACTIVATED BCELL SUBTYPE
2017CG114
COG APEC1621 - NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) MASTER VERSION CONTROL PROTOCOL
2017IS100
HM2017-31: Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20+ B Cell Lymphoma
2017NTLS044
MT2017-11R The Role of Gut Microbiota in Conditioning-Induced Intestinal Barrier Damage in Patients Undergoing Stem Cell Transplantation
2017NTUC078
Building Evidence for Effective Palliative/End of Life Care for Teens with Cancer: FAmily CEntered (FACE) ACP for Teens with Cancer - A multi-site Randomized Control Trial (RCT)
APEC1621SC
COG APEC1621SC - NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) SCREENING PROTOCOL
KIN-2016-25209
The Development of Limb Position Sense during Childhood
PEDS-2016-25172
Collaborative Perinatal Project Minnesota Cohort Follow-up Study (CPP-MN 2.0)

42 trials displayed